Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 42

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 3
Chunk 42
---
 is not patentable or that we elect not to patent, processes that are not easily known, knowable or easily ascertainable,
and for which patent infringement is difficult to monitor and enforce and any other elements of our product candidate discovery and development
processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult
to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our
employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data,
trade secrets and intellectual property by maintaining physical security of our premises and physical and electronic security of our information
technology systems. Agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition,
our trade secrets and intellectual property may otherwise become known or be independently discovered by competitors.

We cannot provide any assurances
that our trade secrets and other confidential proprietary information will not be disclosed in violation of our confidentiality agreements
or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual property could
impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our
trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating
any trade secret.

Third parties may initiate legal proceedings
alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material
adverse effect on the success of our business.

Our commercial success depends
upon our ability to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties.
There is considerable intellectual property litigation in the pharmaceutical industry. While no such litigation has been brought against
us and we have not been held by any court to have infringed a third party’s intellectual property rights, we cannot guarantee that
our product candidates or use of our product candidates do not infringe third-party patents. It is also possible that we have failed to
identify relevant third-party patents or applications. For example, applications filed before November 29, 2000 and certain applications
filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in
the United States and elsewhere are published approximately 18 months after